Page 545«..1020..544545546547..550560..»

Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

Posted: January 5, 2022 at 2:30 am

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present data on broadly neutralizing SARS-CoV-2 antibodies discovered by the company at the upcoming Keystone Symposia Conference: Antibodies as Drugs, being held January 30 – February 2, 2022 both in Keystone, Colo. and virtually.

Visit link:
Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

Posted in Global News Feed | Comments Off on Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

Posted: January 5, 2022 at 2:30 am

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU).

Read this article:
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

Posted in Global News Feed | Comments Off on Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

Posted: January 5, 2022 at 2:29 am

Nationwide search for permanent successor underway Nationwide search for permanent successor underway

Read the original here:
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

Posted in Global News Feed | Comments Off on Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai

Posted: January 5, 2022 at 2:29 am

Clover expects to recruit hundreds of new hires in the area to support preclinical development, process development and pilot manufacturing for novel vaccines and treatments based on Trimer-Tag™ platform and beyond Clover expects to recruit hundreds of new hires in the area to support preclinical development, process development and pilot manufacturing for novel vaccines and treatments based on Trimer-Tag™ platform and beyond

Link:
Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai

Posted in Global News Feed | Comments Off on Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai

PCI Biotech and MDimune announce research collaboration agreement

Posted: January 5, 2022 at 2:29 am

Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company developing innovative drug delivery technologies for modifying cellular and disease processes in many areas of human disease, today announced a preclinical research collaboration that would offer several opportunities for future development.

Original post:
PCI Biotech and MDimune announce research collaboration agreement

Posted in Global News Feed | Comments Off on PCI Biotech and MDimune announce research collaboration agreement

Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

Posted: January 5, 2022 at 2:29 am

See more here:
Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

Posted in Global News Feed | Comments Off on Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

Posted: January 5, 2022 at 2:29 am

ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022

Go here to read the rest:
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

Posted in Global News Feed | Comments Off on Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

Posted: January 5, 2022 at 2:29 am

Press Release

Read this article:
Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

Posted in Global News Feed | Comments Off on Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

The One Food Derms Say You Should Be Eating Everyday For Stem Cell Production (AKA, To Look Years Younger) – SheFinds

Posted: January 5, 2022 at 2:28 am

When it comes to creating an effective and well-rounded approach to anti-aging skincare, its not likely that the foods youre eating ever come into consideration. However, ignoring your diet means youre missing out on a significant opportunity to bolster your complexion from the inside out, failing to make all the changes possible to preserve your appearance from the development of fine lines and wrinkles over time. Your skin is a reflection of your internal health and prioritizing certain foods can increase both collagen and stem cell production under the surface, effectively allowing you to look younger or age more gracefully in combination with the products youre using on the surface.

We checked in with board-certified dermatologist Dr. Anna Chacon to get the rundown on the best food to add into your diet in order to effectively boost stem cell production and smooth your skin, and with some small tweaks to your eating habits your skin will reflect these changes in no time.

Win $500 worth of intimate wellness products

Shutterstock

Not only are cruciferous vegetables great for promoting weight loss through their high fiber content, but these veggies are also known for improving your skin barrier and preserving your youthful appearance as well. According to Chacon, cauliflower, broccoli, kale and cabbage among other fibrous veggies can help to stimulate stem cell production, leading to a brighter complexion. These vegetables are full of these antioxidants and compounds which help to boost the enzymes in the liver that help to counteract harmful toxins we might digest or breathe then, Chacon explains. Within the skin, you might see more of a glow, and less breakouts for example such as acne flares.

Catering to your stem cells can help in the case of anti-aging much like increasing collagen within the body as these cells work to replace other cells which may have died. Making sure to eat a diet that boosts stem cells within your body can help to regenerate anything that has begun to deteriorate across your appearance, smoothing your complexion and keeping signs of aging at bay before they have even developed.

Stem cells are multipotent cells that are present in adult skin and can help when you differentiate into lineages of skin cells on the surface layers, explains Chacon. In layman's terms, stem cells can help to fill in cells that have begun to break down in your skins surface.

Its important to note that theres no cure-all solution to aging, and consuming cruciferous veggies daily wont necessarily turn back the clock on your appearance. However, integrating this group of foods into your diet will allow you to age more gracefully, delaying the appearance of deep wrinkles and fine lines that will naturally develop on your complexion with time. That being said, stem cells are often most useful for repairing damaged and wounded skin, but can also make an impact when it comes to anti-aging.

Some cells on the skin are active during cell renewal which can occur throughout life and also in wound healing of skin after an injury. The intake of vegetables that help to stimulate some self growth are more helpful when we are trying to heal from a major wound or injury, notes Chacon.

Vegetables will never be a bad idea to add to your diet, and with a number of benefits from their fiber content to the slew of other macro nutrients they provide, your body will thank you. Now, instead of merely focusing externally to improve your appearance, you can include your diet in the mix, utilizing cruciferous vegetables to boost stem cell production and allow for a smooth, ageless appearance for years to come. Or at the very least, improve the aging process.

Read the original post:
The One Food Derms Say You Should Be Eating Everyday For Stem Cell Production (AKA, To Look Years Younger) - SheFinds

Posted in Stem Cells | Comments Off on The One Food Derms Say You Should Be Eating Everyday For Stem Cell Production (AKA, To Look Years Younger) – SheFinds

BioRestorative Therapies Awarded an STTR Phase I Grant to – GlobeNewswire

Posted: January 5, 2022 at 2:28 am

MELVILLE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company" or BioRestorative) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Technology Transfer (STTR) Phase I grant for $256,000.The funds will be used specifically to evaluate the therapeutic effects on the Companys hypoxic cultured bone marrow derived mesenchymal stem cells (BRTX-100) after encapsulation with a PEG-peptide hydrogel. The work is being done in collaboration with Dr. Lori Setton, Chair of the Department of Biomedical Engineering at Washington University in St. Louis.

Dr. Setton developed the hydrogel from a PEG backbone conjugated with a proprietary formulation of peptides mimicking laminin and other matrix proteins selected for their ability to modulate cell phenotype and biosynthesis. The STTR aims to define the therapeutic potential and mechanism by which the newly synthesized hydrogel can optimally support the therapeutic delivery of hypoxic cultured bone marrow-derived stem cells.

The National Institutes of Health funds companies with the most innovative, cutting-edge ideas that have the potential to become commercial successes and make important societal impacts, said Lance Alstodt, CEO of BioRestorative Therapies.

We are tremendously grateful and honored to have been awarded this Phase I STTR. This collaboration is an important milestone that demonstrates our commitment to developing and expanding our product pipeline.

All proposals submitted to the NIH SBIR/STTR program undergo a rigorous merit-based review process. Once a small business is awarded a Phase I SBIR/STTR grant (up to $256,000), it becomes eligible to apply for a Phase II (up to $1,000,000). Small businesses with Phase II funding are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.

We are thrilled to collaborate with BioRestorative Therapies on this project. By receiving this grant, we will be able to evaluate the therapeutic benefits of our PEG-peptide hydrogel in combination with BioRestoratives hypoxic cultured stem cells, said Dr. Lori Setton, co-investigator on this project.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate,BRTX-100,is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. TheBRTX-100production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure,BRTX-100is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial usingBRTX-100to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Email:ir@biorestorative.com

View post:
BioRestorative Therapies Awarded an STTR Phase I Grant to - GlobeNewswire

Posted in Stem Cells | Comments Off on BioRestorative Therapies Awarded an STTR Phase I Grant to – GlobeNewswire

Page 545«..1020..544545546547..550560..»